Introduction
Mutation in the tumor suppressor p53 gene is a common somatic genetic drug change found in human cancer (Donehower and Bradley, 1993; Lane, 1994; Levine, 1997; Ozbun and Butel, 1995; Ko and Prives, 1996; Hollstein et al., 1994; Greenblatt et al., 1994) . The level of wild-type p53 in normal cells is very low, but when cells are exposed to genotoxic stimuli p53 levels rise rapidly and initiate a program of cell death or stop the cell cycle at the G1/S boundary, presumably to allow time for DNA repair. This guardian of the genome' response of wild-type p53 (Lane, 1994) is lost in many tumor cells as they have either inactivated their p53 genes by mutation or blocked the activity of p53 through the production of proteins that bind to and neutralize it.
Wild-type p53 acts as a sequence-speci®c DNAbinding protein and transcriptional activator (reviewed in Donehower and Bradley, 1993; Ko and Prives, 1996; Levine, 1997) . All p53 genes from evolutionarily distant species contain ®ve highly conserved regions designated domains I ± V (Soussi et al., 1990, reviewed in Donehower and Bradley, 1993; Ko and Prives, 1996; Levine, 1997) (Figure 1 ). p53 has three functionally distinct domains. The transcriptional activation domain is located within residues 1 ± 42 (Fields and Jang, 1990; Raycroft et al., 1990; O'Rourke et al., 1990; Unger et al., 1992) , while the oligomerization domain is located within residues 320 ± 360 (Wang et al., 1993; Subler et al., 1994a; Sturzbecher et al., 1992; Clore et al., 1994; Lee et al., 1994) . The C-terminal region of p53 also codes for a nonsequence-speci®c nucleic acidbinding domain (reviewed by Ko and Prives, 1996) . The sequence-speci®c DNA-binding domain is located on the central part of the molecule covering domains II ± V (Wang et al., 1993; Bargonetti et al., 1993; Pavletich et al., 1993; Halazonetis and Kandil, 1993; Cho et al., 1994) . p53 mutations found in tumors usually occur within the central part of the molecule such that the mutant proteins are, in general, defective in sequence-speci®c DNA binding and transactivation (Hollstein et al., 1991 Greenblatt et al., 1994, reviewed in Donehower and Bradley, 1993; Ko and Prives, 1996) .
Broadly, three categories of mutations in the p53 gene can be identi®ed (Donehower and Bradley, 1993; Ozbun and Butel, 1995; Levine et al., 1991) : (1)`loss of function' where tumor suppressor activities of p53 are abolished; (2)`dominant negative' where heterooligomeric complex formation between wild-type and mutant p53 results in the inactivation of wild-type p53; and (3)`gain of function' where mutant p53 procures a dominant oncogenic role that does not depend on complex formation with wild-type p53.
Although wild-type p53 is relatively unstable, mutant p53 proteins accumulate to high levels in many cancer cells (reviewed in Ko and Prives, 1996 ; Levine, 1997) . There seems to be a selective pressure in human cancer for the expression of mutant p53 proteins rather than no p53 expression at all. This selection suggests that p53 mutations may directly contribute to the gain of some growth-promoting functions (`gain of function' phenotype) rather than represent the mere loss of wild-type p53 function.
We and others showed that mutant p53 can transactivate promoters of cellular growth-related genes in vivo Chin et al., 1992) . p53 mutants activate the promoters of genes expressing human PCNA, EGFR, MDR-1, vascular endothelial growth factor (VEGF), human IL-6, basic ®broblast growth factor (BFGF) and human HSP70 Chin et al., 1992; Subler et al., 1994b; TsutsumiIshi et al., 1995; Zastawny et al., 1993; Kieser et al., 1994; Ueba et al., 1994; Marguiles and Seghal, 1993) . These observations give rise to the possibility that in cancer cells expressing high levels of mutant p53, the mutant protein may activate transcription of growthpromoting genes resulting in more aggressive growth of these cells. The molecular basis of mutant p53-induced transactivation remains to be determined. Lin et al. (1995) showed that amino acids in positions 22 and 23 in the N-terminal transactivation domain of the mutant protein p53-281G are required for`gain of function' (as judged by tumorigenesis assays) as well as for transactivation of the MDR-1 promoter. This suggests that the transactivation ability of mutant p53 is required for`gain of function'. However, requirements of any other functional domains in transactivation and/or`gain of function' phenotypes of mutant p53 have not been studied.
In this communication, we de®ne the domain required for mutant p53 to transactivate promoters of EGFR, MDR-1 and PCNA genes. Internal deletion mutants of p53-281G have been generated deleting conserved domains I, II, III, IV and V individually, and one deleting amino acids 100 through 300. These mutants have lower transactivation ability than intact p53-281G for EGFR and MDR-1 promoters. Another mutant p53-281G del 393-327 that deletes the oligomerization/nonsequence-speci®c nucleic acid-binding domain of p53 also has signi®cantly lower transactivation ability for EGFR and MDR-1 promoters. Signi®cantly, when expressed constitutively in 10(3) cells, p53-281G del 393-327 was found to be defective in inducing tumor formation in nude mice although intact p53-281G was very ecient.
Results

p53-281G deletion 393-327 dierentially activates dierent promoters
Earlier we have shown that C-terminal deletion of p53-281G up to amino acid 327 causes a signi®cant decrease in transactivation of the human EGFR promoter (Ludes-Meyers et al., 1996) suggesting that the C-terminal oligomerization/nonsequence-speci®c nucleic acid-binding domain is necessary for mutant p53-mediated transactivation. Therefore, we tested whether the requirement for the C-terminal amino acids holds true for some other promoters that have also been shown to be transactivated by mutant p53; for that purpose we used the PCNA and MDR-1 promoters Chin et al., 1992; Dittmer et al., 1993) . We cotransfected Saos-2 human osteosarcoma cells that are devoid of endogenous p53 Figure 1 Schematic representation of p53 and its domain structure Figure 2 p53-281G deletion 393-327 dierentially activates dierent promoters. Saos-2 cells were transiently transfected with 5 mg of PCNA.CAT, MDR-1.CAT or EGFR.CAT promoter/reporter plasmids and 10 mg of the expression plasmid for intact p53-281G or p53-281G del 393-327 (or expression vector alone). After transfection cells were treated as described in Materials and methods and CAT assays were carried out. The average percentages of transactivation compared to that induced by p53-281G are as follows: PCNA.CAT: p53-281G ± 100.00, p53-281G del 393-327 ± 166.1+39.2; MDR-1.CAT: p53-281G ± 100.00, p53-281G del 393-327 ± 6.15+2.03; EGFR.CAT: p53-281G ± 100.00, p53-281G del 393-327 ± 24.70+9.30. Compared to vector alone, p53-281G transactivated the PCNA, EGFR and MDR-1 promoters on average 3-, 8.7-and 42-fold, respectively. Top panels show representative autoradiograms of CAT assays. Lower panels show Western blot analyses carried out with equal amounts of protein from each CAT assay extract used for the upper panels. A monoclonal anti-p53 antibody (PAb1801) was used to detect p53. Closed arrowheads indicate the position of p53-281G, while open arrowheads show p53-281G del with dierent promoter-chloramphenicol acetyl transferase (CAT) constructs and p53-281G or p53-281G del 393-327 (Figure 1 ) expression plasmids (or expression vector alone) as described in Materials and methods. Figure 2 shows a representative example of CAT assay results. p53-281G transactivated all three promoters signi®cantly. Whereas p53-281G del 393-327 could not signi®cantly transactivate the EGFR and MDR-1 promoters, it transactivated the PCNA promoter eciently. It seems that the C-terminally located oligomerization domain or nonsequence-speci®c nucleic acid-binding domain is not essential for transactivation of the PCNA promoter. This suggests that the mechanism of transactivation of dierent promoters by mutant p53 may be dierent.
p53-281G lacking the individual conserved domains transactivates the human EGFR promoter with reduced eciency
Wild-type p53 has ®ve domains (I ± V) ( Figure 1 ) that are phylogenetically conserved (Soussi et al., 1990) . Domains II ± V are critically important for wild-type p53's function, as most of the tumor-derived p53 mutants are mutated at the central part of p53 (reviewed in Ko and Prives, 1996; Levine, 1997) . Involvement of these domains in mutant p53-mediated transactivation has not been studied. We tested whether these phylogenetically conserved domains are required for mutant p53-mediated transactivation of the EGFR promoter using p53-281G as a model tumor-derived p53 mutant. We generated ®ve internal deletion mutants of p53-281G that eliminate conserved domains I ± V individually. It is to be noted that the mutant with domain V deleted does not contain the mutated amino acid at 281. These mutated p53 genes were cloned downstream of the human cytomegalovirus (CMV) immediate-early promoter as described in Materials and methods. Using cotransfection experiments in Saos-2 cells, we tested whether these deletion mutants could transactivate the human EGFR promoter. Multiple transient transfection assays were done, and the data shown in Figure 3 is an example of a typical assay. It is clear that all the internal deletion mutants dramatically reduced the extent of transactivation by p53-281G (compare lane 6 with lanes 1 ± 5). Western blot analysis indicates that all deletion mutants were expressed appreciably (Figure 3, lower panel) . This indicates that the dierence in the transactivation ability observed between dierent deletion mutants and p53-281G is a true representation of transcriptional activation capacity and not due to dierences in the level of the expressed proteins. Figure 3 Deletion mutants of p53-281G lacking the individual conserved domains of p53 transactivate the human EGFR promoter with reduced eciency. Saos-2 cells were transfected with 5 mg of EGFR.CAT promoter/reporter plasmid and 10 mg of the expression plasmid for intact p53-281G, p53-281G del domains I, II, III, or IV, or p53 del domain V (or expression vector alone). After transfection cells were treated as described in Materials and methods and CAT assays were performed. The average percentages of transactivation compared to that induced by p53-281G are as follows: p53-281G ± 100.00, p53-281G del domain I ± 16.06+5.56, p53-281G del domain II ± 32.40+19.10, p53-281G del domain III ± 54.04+7.64, p53-281G del domain IV ± 52.13+17.02 and p53 del domain V ± 10.37+5.36. On average p53-281G activated the EGFR promoter 42-fold compared to the expression vector alone control. The upper panel shows a representative autoradiogram of CAT assays and the lower panel shows the Western blot analysis carried out with equal amounts of protein from each extract used for CAT assays shown in the ®gure. Positions of molecular weight markers are shown on left Figure 4 Deletion mutants of p53-281G lacking the individual conserved domains of p53 transactivate the basal human EGFR promoter with reduced eciency. Saos-2 cells were transfected with 5 mg of EGFR.CAT AvaI del and 10 mg of the expression plasmid for intact p53-281G, p53-281G del domains I, II, III or IV, or p53 del domain V (or expression vector alone). After transfection cells were treated as described in Materials and methods and CAT assays were carried out. The average percentages of transactivation compared to that induced by p53-281G are as follows: p53-281G ± 100.00, p53-281G del domain I ± 16.45+8.38, p53-281G del domain II ± 16.78+7.67, p53-281G del domain III ± 28.09+9.35, p53-281G del domain IV ± 38.53+18.78 and p53 del domain V ± 21.87+1.21. The average transactivation of the EGFR.CAT AvaI del by p53-281G is 38-fold. The upper panel shows a representative autoradiogram of CAT assays, while the lower panel shows the Western blot analysis carried out with equal amounts of protein from each CAT assay extract. Positions of molecular weight markers are shown on left p53-281G lacking the individual conserved domains transactivate the basal human EGFR promoter with reduced eciency Next we analysed whether the full length and the basal EGFR promoters respond in the same way to the conserved domain deletion mutants of p53-281G. We cotransfected Saos-2 cells with the expression plasmid for p53-281G or one of its conserved domain deletion mutants (or expression vector alone) and EGFR.CAT AvaI del. The EGFR AvaI del promoter de®nes the basal EGFR promoter (Deb et al., 1994; Ludes-Meyers et al., 1996) . CAT assays were performed as described in Materials and methods, and Figure 4 shows a representative example of the result. All the internal deletion mutants reduced the extent of transactivation by p53-281G as in the case of the complete EGFR promoter (Figure 3 ). In this case also, the Wetern blot analysis does not indicate major variation in the expression of dierent deletion mutants.
Eect of deletion of the conserved domains on p53-281G-mediated transactivation of the human MDR-1 and PCNA promoters
We also tested whether the conserved domain deletion mutants of p53-281G could activate transcription from promters of two other genes, PCNA and MDR-1. These promoters have also been shown to be transactivated by tumor-derived p53 mutants Chin et al., 1992) . Therefore, we have cotransfected Saos-2 cells with PCNA.CAT (or MDR-1.CAT) and the expression plasmid for p53-281G or one of its deletion mutants (or expression vector alone). We have performed CAT assays as described in Materials and methods. Examples of the CAT assays are shown in Figure 5 . Deletion of conserved domains II ± V had insigni®cant eect on PCNA promoter activity (Figure 5a , compare lane 6 with lanes 2 ± 5). Among the deletion mutants, however, p53-281G del domain I aected the most in some experiments suggesting that perhaps the transactivation domain of p53 may be required for transactivation of the PCNA promoter. On the other hand, transactivation of the MDR-1 promoter was reduced for all the mutants (Figure 5b , compare lane 6 with lanes 1 ± 5). This suggests that although EGFR and MDR-1 promoter activation is sensitive to deletions of conserved domains II ± V in p53-281G, the PCNA promoter activation is not.
Eect of deleting amino acids 100 ± 300 from p53-281G on its transactivation ability Since deletion of the individual conserved domains decreased the eciency, but did not eliminate p53- Figure 5 Eect of deletion of the conserved domains on p53-281G-mediated transactivation of the human PCNA and MDR-1 promoters. Saos-2 cells were transfected with 5 mg of PCNA.CAT or MDR-1.CAT and 10 mg of the expression plasmid for intact p53-281G, p53-281G del domain I, II, III or IV, or p53 del domain V (or expression vector alone). After transfection cells were treated as described in Materials and methods and CAT assays were carried out. (A and B) represent assays with the PCNA and MDR-1 promoters, respectively. The average percentages of transactivation compared to that induced by p53-281G are as follows: PCNA.CAT: p53-281G ± 100, p53-281G del domain I ± 122.25+84.42, p53-281G del domain II ± 95.8+28.74, p53-281G del domain III ± 80.1+29.13, p53-281G del domain IV ± 121.03+45.07 and p53 del domain V ± 117.25+7.79; MDR-1.CAT: p53-281G ± 100.00, p53-281G del domain I ± 25.85+10.49, p53-281G del domain II ± 18.81+5.79, p53-281G del domain III ± 32.43+9.98, p53-281G del domain IV ± 24.95+4.79 and p53 del domain V ± 12.67+1.63. The average transactivation by p53-281G over vector alone are 3-and 48.57-fold for PCNA and MDR-1 promoters, respectively. Representative autoradiograms of CAT assays are shown at the upper panel. Lower panels show the Western blot analyses carried out with equal amounts of protein from each extract used for CAT assays. Positions of molecular weight markers are shown on left Figure 6 Eect of deleting amino acids 100 ± 300 from p53-281G on its transactivation ability. Saos-2 cells were transfected with 5 mg of PCNA.CAT, MDR-1.CAT or EGFR.CAT and 10 mg of the expression plasmid for intact p53-281G or p53 del 100 ± 300 (or expression vector alone). After transfection cells were treated as described in Materials and methods and CAT assays were carried out. The average percentages of transactivation compared to that induced by p53-281G are as follows: PCNA.CAT: p53-281G ± 100.00, p53 100 ± 300 ± 196+31.66; MDR-1.CAT: p53-281G ± 100.00, p53 del 100 ± 300 ± 9.20+2.97; EGFR.CAT: p53-281G ± 100.00, p53 del 100 ± 300 ± 33.07+12.07. On average the PCNA promoter was activated threefold by p53-281G. Lower panels show Western blot analyses carried out with equal amounts of protein from each CAT assay extract used for panels above. Closed arrowheads indicate the position of p53-281G, while open arrowheads show p53 del 100 ± 300 281G-mediated transactivation of the EGFR and MDR-1 promoters (moreover the activity of PCNA promoter was not even reduced), we were interested to determine how elimination of several of the conserved domains of p53-281G would aect its ability to transactivate these promoters. Using PCR we deleted the amino acids of p53-281G between positions 100 ± 300 that includes conserved domains II ± V (Figure 1 ) and covers the entire DNA-binding region of wild-type p53 (reviewed in Ko and Prives, 1996; Levine, 1997) . Transactivation was assayed by performing transient transcription analysis using CAT assays as described in Materials and methods. We have used all three promoter-CAT constructs, EGFR.CAT, PCNA.CAT and MDR-1.CAT. Data shown in Figure 6 show that p53 del 100 ± 300 failed to transactivate the MDR-1 promoter (compare lanes 5 and 6), while it could only partially activate the human EGFR promoter (compare lanes 8 and 9) . Surprisingly, the PCNA promoter activity was slightly enhanced by this deletion (compare lanes 2 and 3) suggesting, again, that the mode of transactivation of the PCNA promoter by p53-281G is dierent from that of the EGFR and MDR-1 promoters.
p53-281G deletion 1 ± 58 fails to activate dierent promoters
Since the PCNA promoter was transactivated by deletion mutants of p53-281G that failed to significantly transactivate the EGFR and MDR-1 promoters, we tested whether the transactivation domain of p53 is required for activation of the PCNA promoter. We cotransfected Saos-2 cells with dierent promoter-CAT constructs and p53-281G or p53-281G del 1 ± 58 (or expression vector alone) as described in Materials and methods. Figure 7 shows a representative example of CAT assay results. In this case p53-281G del 1 ± 58 failed to signi®cantly transactivate all the three promoters. This suggests that the transactivation domain of mutant p53 is required for mutant p53-mediated transactivation.
Removal of the C-terminal oligomerization/nonsequencespeci®c nucleic acid-binding domain reduces the oncogenic potential of p53-281G
We studied the relationship between the transactivation property of tumor-derived p53 mutant p53-281G and its`gain of function' phenotype. To assay`gain of function' we have utilized 10(3) murine ®broblast cells that are devoid of endogenous p53. These cells are not tumorigenic in nude mice. Earlier it has been shown that if a mutant p53, such as p53-281G, is expressed in these cells constitutively, the mutant p53 expressing cells become tumorigenic (Dittmer et al., 1993; Lin et al., 1995) . Figure 7 p53-281G deletion 1 ± 58 fails to transactivate dierent promoters. Saos-2 cells were transiently transfected with 5 mg of PCNA.CAT, MDR-1.CAT or EGFR.CAT promoter/reporter plasmids and 10 mg of the expression plasmid for intact p53-281G or p53-281G del 1 ± 58 (or expression vector alone). After transfection cells were treated as described in Materials and methods and CAT assays were carried out. The average percentages of transactivation compared to that induced by p53-281G are as follows: PCNA.CAT: p53-281G ± 100.00, p53-281G del 1 ± 58 ± 12.46+11.0; MDR-1.CAT: p53-281G ± 100.00, p53-281G del 1 ± 58 ± 6.80+4.27; EGFR.CAT: p53-281G ± 100.00, p53-281G del 1 ± 58 ± 10.86+0.81. Compared to vector alone, p53-281G transactivated the PCNA, MDR-1 and EGFR promoters on average 21.8-, 9.5-and 10.7-fold, respectively. Top panels show representative autoradiograms of CAT assays. Lower panels show Western blot analyses carried out with equal amounts of protein from each CAT assay extract used for the upper panels. A monoclonal anti-p53 antibody (PAb421) that recognizes the C-terminus was used to detecte p53 Figure 8 Expression of p53-281G and its deleted form in 10(3) cells stably transfected with p53-281G or with p53-281G del 393-327. 10(3) cell lines stably expressing p53-281G or p53-281G del 327 ± 393 were constructed and maintained as described in Materials and methods. Protein extracts from cells carrying the expression vector (lanes 1 and 2), p53-281G (lanes 3 and 4) or p53-281G truncated at amino acid 327 (lanes 5 and 6) were obtained by three successive cycles of freezing and thawing. Western blots were prepared by standard procedures (Materials and methods). Equal amounts of protein were loaded in each well. The blot was developed using the monoclonal antibody PAb 1801. Positions of molecular weight markers are shown
We have generated a number of cell lines derived from 10(3) cells that express p53-281G and p53-281G del 393-327 (Figure 8 ) and tested whether they generate tumors in nude mice. Results of these experiments are shown in Table 1 . 10(3) cells alone (or stably transfected with vector alone) did not generate tumors when observed for more than 6 months. However, p53-281G expressing cell clones all generated tumors. Visible tumor formation started within 3 ± 4 weeks after injection. Signi®cantly, none of the mice injected with two independent clones of 10(3) cells expressing p53-281G del 393-327 generated any tumor within 6 months after injection.
Discussion
We have previously shown that certain tumor-derived p53 mutants can transactivate promoters of growthrelated genes such as PCNA and EGFR (Deb et al., , 1994 Ludes-Meyers et al., 1996) . A number of other laboratories have made similar observations (Chin et al., 1992; Tsutsumi-Ishi et al., 1995; Zatsawny et al., 1993; Kieser et al., 1994; Ueba et al., 1994; Marguiles and Seghal, 1993) . Some tumorderived p53 mutants have`gain of function' properties suggesting that the mutational change in the p53 molecule has induced oncogenic functions (Dittmer et al., 1993; Wolf et al., 1984; Shaulski et al., 1991; Hsiao et al., 1994) . Arnold-Levine and his coworkers (Dittmer et al., 1993; Lin et al., 1995) showed that p53-281G can induce increased tumorigenicity in 10(3) cells when constitutively expressed under the control of a CMV immediate-early promoter. Further, they demonstrated that a double substitution at amino acids 22 and 23 of p53-281G destroyed its transactivation capacity (as judged by its ability to transactivate the MDR-1 promoter) as well as its`gain of function' property (as judged by decreased tumorigenicity of 10(3) cells constitutively expressing the mutant). This observation suggested a direct relationship between mutant p53's transactivation ability and its`gain of function' property. To analyse which regions of a tumor-derived p53 mutant may contribute to the`gain of function' phenotype, we carried out a series of experiments using p53-281G mutants and a set of promoter-reporter constructs derived from genes implicated in regulation of cell growth such as EGFR and PCNA.
We have demonstrated that the C-terminally located segment 393-327 in p53-281G is required for transactivation of the human EGFR and MDR-1 promoters (Ludes-Meyers et al., 1996; this report). The C-terminal region of p53 between amino acids 393 and 327 contains its oligomerization (tetramerization) and nonsequence-speci®c DNA-binding domains (reviewed by Ko and Prives, 1996) . Thus, it is reasonable to speculate that proper oligomeric forms of mutant p53 are necessary for transactivation. Perhaps proper oligomeric forms are needed to have ecient protein ± protein interaction necessary for mutant p53's function. It is also possible that the nonsequence-speci®c DNA-binding domain of tumor-derived p53 mutants interacts with promoter DNA, helping nucleation of transcriptional machinery. The Cterminal region also has binding sites for dierent proteins involved in transcription, e.g. TBP, TFIIH (reviewed by Ko and Prives, 1996) . Also, the Cterminal region is required for mutant p53-mediated binding to nuclear matrix/scaold attachment regions (Mueller et al., 1996) . Since the C-terminal region of p53 has multiple subdomains, our data do not rule out the possibility that the requirement for the C-terminal segment up to amino 327 can be due to one or more of several reasons such as, loss of oligomerization, loss of nonsequence-speci®c DNA binding, or loss of crucial protein ± protein interactions. Further studies are required to establish the role of each functional subdomain near the C-terminus to decipher the mechanism of transactivation mediated by tumorderived mutant p53.
p53-281G deletion mutants that eliminate individual conserved domains could not transactivate the EGFR and MDR-1 promoters (Figures 3 ± 6 and 8) suggesting a role(s) for these regions in mutant p53-mediated transactivation. The central region of wild-type p53 (amino acids 100 ± 300) is involved in sequence-speci®c DNA binding. Since tumor-derived mutants of p53 are, in general, defective in sequence-speci®c DNA binding, it gives rise to the possibility that for mutant p53-mediated transactivation the conserved domains are required for a particular structural conformation or for crucial protein ± protein interactions. Alternatively, the conserved domains may be responsible for DNA binding to an unknown sequence element that is directly or indirectly involved in mutant p53-mediated transactivation.
We have observed that p53-281G del 393-327 could transactivate the PCNA promoter although it could not activate the EGFR and MDR-1 promoters. Therefore, the PCNA promoter transactivation perhaps does not require proper oligomerization of p53-281G. Thus, there is a dierence in the mechanism of transactivation by p53-281G of the PCNA and EGFR (or MDR-1) promoters. The PCNA promoter activation by p53-281G, however, requires the transactivation domain (Figure 7 ). Since the PCNA promoter is transactivated by p53-281G deletion mutants that eliminate the conserved domains II ± V of p53 ( Figure  5a ), it is possible that the PCNA promoter activation takes place through protein ± protein interactions mediated via the transactivation domain. The transactivation of the EGFR and MDR-1 promoters by p53-281G, however, requires the C-terminal segment from amino acid 393 to 327 as well as the conserved 6/12 3/6 3/6 3/6 3/6 3/6 3/6 0/12 0/6 0/6 6/6 6/6 0/6 0/6 domains ( Figures 3 ± 6 and 8 ). These observations strongly suggest that the domain requirements for mutant p53-mediated transactivation may vary depending on the promoter tested. It is also possible that tumor-derived p53 mutants increases PCNA promoter activity through an indirect mechanism, perhaps through their eect on the cell cycle. Tumorigenicity data presented here and elsewhere (Dittmer et al., 1993; Wolf et al., 1984; Shaulski et al., 1991; Hsiao et al., 1994) indicate that expression of some tumor-derived p53 mutants in cell(s) without endogenous p53 enhances the oncogenicity of these cells. These ®ndings support the`gain of function' hypothesis. When constitutively expressed in 10(3) cells, p53-281G, a transcriptionally active p53 mutant, increases the tumorigenicity of these cells (Table 1) . However, deletion of amino acids 393 to 327 renders p53-281G inactive in transactivation of the EGFR and MDR-1 promoters but not of the PCNA promoter. This deletion mutant failed to induce tumorigenicity when expressed constitutively in 10(3) cells, directly correlating transactivation ability with enhancement of oncogenicity. Since p53-281G del 393-327 can still transactivate the human PCNA promoter (Figure 2) , the`gain of function' phenotype cannot be assayed by mutant p53-mediated transactivation of the PCNA promoter. Thus, transactivation of the human EGFR or MDR-1 promoter is a better measure for the`gain of function' phenotype than PCNA promoter transactivation. Our tumorigenicity data ( Table 1 ) also show that the C-terminal region (amino acid 393-327) is necessary for the`gain of function' phenotype. Since the transactivation data presented are from experiments that used Saos-2 and not 10(3) cells, we have evaluated the eect of expression of p53-281G and its deletion mutants on the EGFR promoter activity using 10(3) cells also. The results of these analyses (data not shown) indicated that in 10(3) cells the regulation of the EGFR promoter by p53-281G and its derivatives used in this study is similar to that seen in Saos-2 cells.
Taken together our data suggest that the`gain of function' phenotype requires the transactivation function of tumor-derived p53 mutants. It is possible that tumor-derived p53 mutants transactivate a number of growth-promoting genes resulting in a tumorigenic phenotype. In the future it might be possible to identify genes that are speci®cally transactivated by these mutants unraveling pathways of oncogenesis further.
Materials and methods
DNA plasmids
The p53 expression plasmids contain mutant human p53 cDNA (or a deletion mutant) (Figure 1 ) under the regulation of the human CMV immediate-early promoter in the pCMV-Bam expression vector (Hinds et al., 1990; Subler et al., 1992) . The C-terminal deletion derivative p53-281G del 393-327 was generated in the context of the human p53-281G cDNA as described (Ludes-Meyers et al., 1996) . All the internal deletion mutants were generated by PCR, and their sequence veri®ed by dideoxy sequencing using a Sequenase kit (United States Biochemicals, Inc). The mutants with deletion of conserved domains I, II, III and IV respectively, were all generated in the context of p53-281G. The mutants that deleted domain V and amino acids 100 ± 300 eliminated the mutation at amino acid 281.
The CAT plasmids utilized the Escherichia coli CAT gene under the transcriptional control of (a) the complete EGFR promoter (716 to 71100) (EGFR.CAT, Deb et al., 1994) ; (b) the EGFR basal promoter (716 to 7105) (EGFR del AvaI.CAT, Deb et al., 1994) ; (c) the complete PCNA promoter (+275 to 71269, Deb et al., 1992) ; and (d) the MDR-1 promoter sequences (71073 to +1, Chin et al., 1992; Chen et al., 1990; Dittmer et al., 1993) .
Cell culture and transfection 10(3) cells are murine ®broblasts devoid of endogenous p53 (Harvey and . These cells are maintained as described (Dittmer et al., 1993; Lin et al., 1995) . Saos-2 cells were cultured as described previously . Cells were transfected by the calcium phosphate-DNA coprecipitation method as described . In a typical experiment 5610 6 cells were cotransfected with 5 mg of a CAT construct and 10 mg of a p53 (p53-281G or one of the deletion mutants) expression plasmid (or 10 mg of the expression vector without p53 sequences as a negative control). All transient transfection experiments were repeated multiple times (three times or more).
Chloramphenicol acetyltransferase assay
Cells were harvested 36 ± 40 h post-transfection and lyzed by three successive cycles of freezing and thawing. Extracts were normalized for protein concentration and assayed for CAT enzyme activity (Ludes-Meyers et al., 1996) . Because wild-type p53 inhibits and mutant p53 activates dierent promoters to varying extents Ginsberg et al., 1991; Lechner et al., 1992; Santhanam et al., 1991; Subler et al., 1992) , it was not possible to use an internal control such as pSVbGal or RSVbGal (Ludes-Meyers et al., 1996) . A similar situation has been recognized for SV40 T antigen-mediated regulation of promoters (Gruda et al., 1993) . Therefore, multiple independent experiments (three or more) were done to determine the standard deviations. CAT activity was detected by thin-layer chromatographic separation of [ 14 C]chloramphenicol from its acetylated derivatives followed by autoradiography. Quantitation was done using a Phosphorimager (Molecular Dynamics), and standard deviations were calculated.
Establishment of stable 10(3) cell lines expressing p53-281G and p53-281G del 393-327: tumorigenesis in nude mice 10(3) cells have been transfected with vector alone (pCMV Bam neo, Hinds et al., 1990; Subler et al., 1992) or expression plasmids for the tumor-derived p53 mutant p53-281G or p53-281G del 393-327 using the calcium phosphate precipitation technique . Forty-eight hours after transfection, cells were washed, trypsinized, subcultured at 1 : 4, and plated into selective media supplemented with 200 mg/ml G-418 (active concentration). Cells were maintained in the selective media with twice weekly changes of media. After 14 ± 21 days in selective media, cells from individual G-418-resistant colonies were isolated and expanded into cell lines. Western blot analyses were used to show that mutant p53 was expressed in these cell lines.
Tumorigenicity assay
The tumorigenic potential of 10(3) cells either alone (untransfected) or stably transfected with p53-281G or p53-281G del 393-327 (or expression vector alone) was tested using nude mice. Cells (5610 6 per site) were subcutaneously injected into¯anks of athymic nude mice (National Cancer Institute) and tumor development was monitored as described (Dittmer et al., 1993) .
Western blot analysis
Western blot analysis was carried out after SDS polyacrylamide gel electrophoresis using monoclonal antibodies against p53 and a kit (Promega) for labeling with an alkaline phosphatase-conjugated secondary antibody. Manufacturer's protocol was followed for this procedure.
